| abstract |
The present invention provides compounds that are novel antagonists to the D 1 receptor and methods for preparing such compounds. In another embodiment, the present invention provides pharmaceutical compositions comprising such D 1 receptor antagonists, and uses them, CNS disorders, obesity, metabolic disorders, eating disorders and diabetes, such as bulimia Provide a method of treatment. In many embodiments, the present invention provides a novel class of n-arylamidines as D 1 receptor antagonists, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, A method of preparing a pharmaceutical composition or formulation comprising such a compound as described above, and one type associated with obesity, metabolic disorders, CNS disorders, or obesity using such compounds or pharmaceutical compositions A method for treating, preventing, inhibiting or ameliorating the above diseases is provided. |